



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 39/095, 39/39, 9/127, 39/385		A1	(11) International Publication Number: WO 99/61053 (43) International Publication Date: 2 December 1999 (02.12.99)
(21) International Application Number: PCT/US99/11977		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 28 May 1999 (28.05.99)			
(30) Priority Data: 60/087,351 29 May 1998 (29.05.98) US 60/106,446 30 October 1998 (30.10.98) US			
(71) Applicant (<i>for all designated States except US</i>): CHIRON CORPORATION [US/US]; 4560 Horton Street, Emeryville, CA 94608 (US).			
(72) Inventors; and		Published	
(75) Inventors/Applicants (<i>for US only</i>): GRANOFF, Dan, M. [US/US]; 10 Creston Road, Berkeley, CA 94708 (US). AABERGE, Ingeborg, S. [NO/NO]; Statens Institutt for Folkehelse, P.O. Box 4404, N-0403 Oslo (NO). HANEBERG, Bjorn [NO/NO]; Statens Institutt for Folkehelse, P.O. Box 4404, N-0403 Oslo (NO). HOLST, Johan [NO/NO]; Statens Institutt for Folkehelse, P.O. Box 4404, N-0403 Oslo (NO). RAFF, Howard [US/US]; 296 Greene Street, Mill Valley, CA 94941 (US).		With international search report.	
(74) Agent: HARBIN, Alisa, A.; Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA 94662-8097 (US).			

(54) Title: COMBINATION MENINGITIDIS B/C VACCINES

(57) Abstract

The present invention is directed to a combination vaccine for *Neisseria meningitidis* comprising outer membrane proteins from serogroup B and oligosaccharides from serogroup C, and its use for the prevention or treatment of disease.